BMSplus – the portal for health care professionals
Our Range of Topics at a Glance
Extensive media library
Access a wide range of resources, including webinars, podcasts, HCP materials, and patient brochures, all designed to support your professional needs.
Clinical data
Events and Congresses
Clinical Research
Your BMS team
Dive into our disease areas: explore resources, research, and insights
News and recent approvals
Gastrointestinal Cancer
January 2025 - OPDIVO® in combination with YERVOY® is now approved for the first-line treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) unresectable or metastatic colorectal cancer.
Thoracic Cancer
December 2024 - OPDIVO® in combination with YERVOY® and 2 cycles of platinum-based chemotherapy is now approved for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults with no EGFR or ALK genomic tumor aberrations.
Genitourinary Cancer
August 2024 - OPDIVO® is now approved in combination with cisplatin/gemcitabine chemotherapy for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma with PD-L1 tumor expression ≥1%.
Gastrointestinal Cancer
March 2024 – OPDIVO® (nivolumab) in combination with chemotherapy containing oxaliplatin and fluoropyrimidine is indicated for the first-line treatment of adult patients with inoperable, locally advanced or metastatic gastric cancer, gastroesophageal junction cancer, and distal oesophageal adenocarcinoma with Combined Positive Score (CPS) PD-L1 expression ≥ 10.
Melanoma
Februar 2024 – OPDUALAG® (nivolumab/relatlimab) is now reimbursed for the first-line treatment of adults with metastatic melanoma with PD-L1 < 1% expression.
Melanoma
November 2023 – Q4W 480 mg dosing with OPDIVO® (nivolumab) is approved in all melanoma indications.
Q4W dosing is approved for all Nivolumab monotherapy as well as monotherapy maintenance after Nivolumab + Ipilimumab combination treatment in melanoma.
01/2025 ONC-CH-2500001